Metabolites of glp1r agonists

A compound of Formula XA-3 or XA-4:

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring T1 is phenyl or pyridinyl, wherein each of the phenyl or pyridinyl is substituted with 1, 2, 3, or 4 independently selected R500, wherein each R500 is independently F, Cl, —CN, or —OR501, or two adjacent R500 together form a moiety of —O—CR502R503—O— that is fused to the phenyl or pyridinyl of Ring T1, and wherein when the phenyl or pyridinyl of ring T1 is not substituted with a moiety of —O—CR502R503—O—, then it is at least substituted with one —OR501;
• each R501 is independently —C(R504R505)R506;
• R502 is H or —C1-3alkyl, wherein the —C1-3alkyl is substituted with 0 to 1 OH;
• R503 is independently phenyl or a 6-membered heteroaryl, wherein each of the phenyl or pyridinyl is substituted with 0, 1, 2, or 3 independently selected R507;
• each of R504 and R505 is H or —C1-3alkyl, wherein the —C1-3alkyl is substituted with 0 to 1 OH;
• each R506 is independently phenyl or a 6-membered heteroaryl, wherein each of the phenyl or pyridinyl is substituted with 0, 1, 2, or 3 independently selected R508;
• each R507 is independently halogen, —CN, —C1-3alkyl, or —OC1-3alkyl, wherein each of the C1-3alkyl and OC1-3alkyl is substituted with 0 to 3 F atoms;
• each R508 is independently halogen, —CN, —C1-3alkyl, or —OC1-3alkyl, wherein each of the C1-3alkyl and OC1-3alkyl is substituted with 0 to 3 F atoms;
• each R3 is independently F, —OH, —CN, —C1-3alkyl, —OC1-3alkyl, or —C3-4cycloalkyl, or 2 R3s may together cyclize to form —C3-4spirocycloalkyl, wherein the alkyl of C1-3alkyl and OC1-3alkyl, cycloalkyl, or spirocycloalkyl may be substituted as valency allows with 0 to 3 F atoms and with 0 to 1 —OH;
• q is 0, 1, or 2;
• R4 is —C1-3alkyl, —C0-3alkylene-C3-6cycloalkyl, —C0-3alkylene-R5, or —C1-3alkylene-R6, wherein said alkyl may be substituted as valency allows with 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent selected from —C0-1alkylene-CN, —C0-1alkylene-ORO, and —N(RN)2, and
• wherein said alkylene and cycloalkyl may be independently substituted as valency allows with 0 to 2 substituents independently selected from 0 to 2 F atoms and 0 to 1 substituent selected from —C0-1alkylene-CN, —C0-1alkylene-ORO, and —N(RN)2;
• R5 is a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:
• 0 to 1 oxo (═O),
• 0 to 1 —CN,
• 0 to 2 F atoms, and
• 0 to 2 substituents independently selected from —C1-3alkyl and —OC1-3alkyl, wherein the alkyl of C1-3alkyl and OC1-3alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:
• 0 to 3 F atoms,
• 0 to 1 —CN, and
• 0 to 1 —ORO;
• R6 is a 5- to 6-membered heteroaryl, wherein said heteroaryl may be substituted with 0 to 2 substituents as valency allows independently selected from:
• 0 to 2 halogens,
• 0 to 1 substituent selected from —ORO and —N(RN)2, and
• 0 to 2 —C1-3alkyl, wherein the alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:
• 0 to 3 F atoms, and
• 0 to 1 —ORO;
• each RO is independently H, or —C1-3alkyl, wherein C1-3alkyl may be substituted with 0 to 3 F atoms;
• each RN is independently H, or —C1-3alkyl;
• Z1 is CH or N;
• Z2 and Z3 are each independently —CRZ or N, provided that when Z1 or Z3 is N, Z2 is —CRZ;
• and
• each RZ is independently H, F, Cl, or —CH3.